Rhodes Pharmaceuticals LLC announced today that its application (ANDA205601) for the generic sublingual combination of buprenorphine and naloxone has been granted FDA approval, a move which significantly bolsters the company’s strategic position in the high-margin opioid addiction treatment market. This victory is expected to expedite commercial availability of a low-cost alternative, placing further competitive pressure on branded formulations in a rapidly shifting recovery landscape.